arrow
A

A. Albertí

universita di modena e reggio emilia hospital
H指数:74
被引数:2.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients: Results of the Italian cohort of a post-marketing observational study

格列卡普韦/皮布伦他韦治疗慢性丙型肝炎患者的有效性和安全性: 一项上市后观察性研究的意大利队列结果

2021-05-014
PREAI
Impact of HBV infection in HCV/HBV coinfected patients treated with DAAs IN Northern Italy
2020-02-010
PREAI
Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure
2019-12-0171
PREAI
Efficacy and safety of elbasvir/grazoprevir in a large real-life cohort of HCV-infected patients
2019-04-011
PREAI
Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir for retreatment of chronic hepatitis C patients with a previous failure to direct-acting antivirals: A real-life study from the NAVIGATORE Lombardia and Veneto Networks
2019-04-011
PREAI
Treatment of 320 genotype 3 cirrhotic patients with 12 weeks of sofosbuvir/velpatasvir with or without ribavirin: Real life experience from Italy
2019-04-011
PREAI
Efficacy and safety of Elbasvir/Grazoprevir in a large real-life cohort of HCV-infected patients
2019-02-010
PREAI
Effectiveness and safety of Sofosbuvir/Velpatasvir/Voxilaprevir for retreatment of chronic hepatitis C patients with a previous failure to direct-acting antivirals: a real-life study from the Navigatore Lombardia and Veneto Networks
2019-02-010
PREAI
Treatment of 320 genotype 3 cirrhotic patients with 12 weeks Sofosbuvir/Velpatasvir with or without ribavirin: real life experience from Italy
2019-02-010
PREAI
Daclatasvir-based regimens in HCV cirrhosis: experience from the Italian early access program
2019-01-247
OAAI
Real life experiences in HCV management in 2018
2019-01-157
OAAI
Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study

接受DAAs治疗的晚期丙型肝炎患者新诊断的肝细胞癌: 一项前瞻性人群研究

2018-08-01127
PREAI
Effectiveness and safety of DAA treatment for recurrent hepatitis C after liver transplantation: The NAVIGATOR Lombardia-Veneto network
2018-02-010
PREAI
Evolution of HCV treatments with direct acting antivirals between 2014 and 2017 in 8637 HCV patients in a real world setting: A report from the Lombardia Network and Navigator Study Group
2018-02-010
PREAI